

TEA TREE OIL IN ACNE VULGARIS: MECHANISMS OF ACTION, CLINICAL EVIDENCE, AND DERMATOLOGICAL SAFETY

Mircea BEȚIU¹, Eugeniu RUSSU^{2,*}, Mihaela ROTARI¹, Valeriu DAVID³

¹ Department of Dermatovenereology, Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Republic of Moldova

² “Nicolae Testemițanu” State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

³ Laboratory of Morphology, Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Republic of Moldova

Abstract

Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit with multifactorial pathogenesis, involving follicular hyperkeratinization, increased sebum production, *Cutibacterium acnes*, microbiome imbalance, inflammation, and variable therapeutic response. Although current guideline-based treatments include topical retinoids, benzoyl peroxide, antibiotics, hormonal therapy, and isotretinoin, limitations such as irritation, adherence difficulties, antimicrobial resistance, and patient preference for natural products have increased interest in complementary topical agents, and Tea tree oil, derived from *Melaleuca alternifolia*, has been investigated as a potential adjunctive option in acne vulgaris due to its antimicrobial, anti-inflammatory, antioxidant, and antibiofilm properties. These mechanisms are biologically relevant to acne pathogenesis, particularly regarding *C. acnes* activity, inflammatory lesion development, and microbial persistence, and however, clinical evidence remains heterogeneous, and therapeutic interpretation is limited by differences in oil composition, concentration, formulation, study design, and outcome measures. Moreover, dermatological safety is essential, as tea tree oil may cause irritant or allergic contact dermatitis, especially when used undiluted. This review summarizes its mechanisms, clinical evidence, formulation relevance, and safety limitations.

Keywords: tea tree oil, acne vulgaris, *Cutibacterium acnes*, essential oils, antimicrobial activity, dermatological safety

Introduction

Acne vulgaris is one of the most common chronic inflammatory skin diseases, affecting adolescents and adults with variable clinical severity and considerable psychosocial impact, and although frequently perceived as a benign or self-limited disorder, acne can persist beyond adolescence, especially in adult women, and may lead to post-inflammatory hyperpigmentation, scarring, emotional distress, reduced self-esteem, and impaired quality of life. Its clinical spectrum ranges from comedonal lesions to inflammatory papules, pustules, nodules, and, in severe cases, scarring disease. The multifactorial nature of acne explains both its chronicity and the variability of therapeutic response among patients [1].

Current understanding of acne pathogenesis involves follicular hyperkeratinization, increased sebum production, colonization by *Cutibacterium acnes*, inflammation, and alterations in the skin microbiome, and standard management depends on disease severity and

includes topical retinoids, benzoyl peroxide, topical or systemic antibiotics, hormonal therapies, and oral isotretinoin in selected severe cases, and recent therapeutic strategies have also explored nanotechnology-based delivery systems to improve drug penetration, stability, tolerability, and targeted action within the pilosebaceous unit [1,2].

Evidence-based guidelines emphasize individualized treatment, combining lesion type, severity, patient age, skin characteristics, risk of scarring, tolerability, pregnancy status, and previous therapeutic response, and however, conventional acne treatments may be limited by irritation, dryness, photosensitivity, adherence problems, cost, and concerns regarding antimicrobial resistance, and these limitations have stimulated interest in complementary topical agents with antimicrobial, anti-inflammatory, and antioxidant properties, particularly when intended as adjunctive options rather than replacements for guideline-based therapy [2,3].

Adult acne adds further complexity because it may differ from adolescent acne in distribution, chronicity, hormonal influence, relapse tendency, and therapeutic expectations. This has increased interest in well-tolerated topical approaches that may support long-term disease control, and within this context, tea tree oil has gained attention as a natural essential oil with potential relevance in acne vulgaris, providing the rationale for reviewing its mechanisms of action, available clinical evidence, and dermatological safety profile [4].

We have made a schematic presentation of the pathogenic mechanisms of acne vulgaris, the main limitations of conventional therapy, and the biological rationale for investigating tea tree oil as a complementary topical agent is presented in Figure 1.




Figure 1. Rationale for investigating tea tree oil as a complementary topical approach in acne vulgaris.

Acne vulgaris is driven by multiple interconnected mechanisms, including follicular hyperkeratinization, increased sebum production, *colonization by Cutibacterium acnes*, microbiome imbalance, inflammation, and oxidative stress, and these processes contribute to comedonal and inflammatory lesions, with potential progression toward post-inflammatory hyperpigmentation, scarring, and psychosocial burden, and conventional therapies remain essential, but their use may be limited by irritation, dryness, adherence issues, cost, and concerns regarding antimicrobial resistance, and tea tree oil has been investigated as a complementary topical agent because of its antimicrobial, anti-inflammatory, antioxidant, and potential antibiofilm properties [1-4].

Pathophysiology of acne vulgaris: inflammation, microbiome, and antibiotic resistance

Acne vulgaris is a multifactorial inflammatory disease of the pilosebaceous unit, in which follicular hyperkeratinization, increased sebum production, microbial dysbiosis, and immune activation interact in a dynamic pathogenic sequence and although *Cutibacterium acnes* has long been considered a central microbial factor, current evidence suggests that acne cannot be explained only by bacterial proliferation. Instead, the inflammatory response, the virulence profile of *C. acnes*, and the host immune reaction are essential determinants of lesion development and disease severity [5].

A major recent advance in acne pathophysiology is the recognition of the relationship between *C. acnes* and the Th17 inflammatory pathway, and *C. acnes* strains can stimulate pro-inflammatory cytokine production and promote Th17-mediated immune responses, contributing to perifollicular inflammation and the transition from microcomedones to papules and pustules, and this supports the concept that inflammation is not merely a late consequence of follicular obstruction, but an early and active process in acne lesion formation [5].

The skin microbiome also plays an important role in acne. Rather than the simple presence or absence of *C. acnes*, disease expression appears to depend on microbial balance, phylotype distribution, strain-level virulence, and interactions with other members of the cutaneous microbiota. Specific *C. acnes* phylotypes may be more strongly associated with inflammatory acne, whereas a more balanced microbiome may contribute to skin homeostasis, and this microbiome-based perspective explains why antimicrobial strategies should ideally reduce pathogenic activity without excessively disrupting normal skin microbial ecology [6].

Antibiotic resistance represents an additional therapeutic challenge, and the increasing prevalence of antibiotic-resistant *C. acnes* strains limits the long-term effectiveness of conventional antimicrobial therapy and reinforces the need for non-antibiotic or adjunctive approaches, and agents with antimicrobial, anti-inflammatory, antibiofilm, or microbiome-modulating properties may be particularly relevant, provided that their efficacy and safety are critically evaluated [7], the main pathogenic mechanisms discussed in this section, together with their relevance to the evaluation of tea tree oil as a potential adjunctive topical agent, are summarized in Table 1.

Table 1. Key pathogenic mechanisms in acne vulgaris

Pathogenic component	Role in acne development	Relevance to tea tree oil review	Ref.
Follicular hyperkeratinization	Promotes microcomedone formation and follicular obstruction	Creates the initial environment for inflammatory lesion development	[5]
Inflammation / Th17 pathway	Drives perifollicular inflammation and papulopustular lesions	Supports interest in anti-inflammatory topical agents	[5]
<i>Cutibacterium acnes</i> phylotypes	Different strains may show different virulence patterns	Relevant for antimicrobial and strain-targeted effects	[6]
Skin microbiome imbalance	Alters cutaneous homeostasis and inflammatory response	Important when considering microbiome-friendly alternatives	[6]
Antibiotic-resistant <i>C. acnes</i>	Reduces the efficacy of conventional antibiotic therapy	Strengthens the rationale for adjunctive non-antibiotic options	[7]

Tea tree oil and essential oils as topical approaches in acne vulgaris

Tea tree oil, derived from *Melaleuca alternifolia*, has gained particular attention among essential oils used in dermatology for its antimicrobial, anti-inflammatory, and antioxidant properties, and in the context of acne vulgaris, these effects are relevant because the disease involves microbial dysbiosis, inflammatory activation, follicular obstruction, and oxidative stress, and the major biologically active component of tea tree oil is generally considered to be terpinen-4-ol, although its clinical activity is likely related to interactions among multiple monoterpenes and other volatile compounds, and this chemical complexity may explain both its broad biological activity and the variability observed between different formulations or commercial preparations [8].

The rationale for using tea tree oil in acne is mainly based on its work against acne-associated microorganisms and of course its potential to reduce the burden of inflammatory lesions, and the literature suggests that tea tree oil can diminish inflammatory lesions in patients, especially papules and pustules, while exerting antibacterial effects against *Cutibacterium acnes* and other skin-associated bacteria, and existing studies, differ in design, concentration, formula, duration of treatment and evaluation of results, making it difficult to draw definitive conclusions on efficacy and safety, so tea tree oil should be interpreted as an additional topical option rather than as a standalone substitute for evidence-based acne treatment [8].

Essential oils more broadly have been investigated in acne because many contain bioactive compounds with antimicrobial, anti-inflammatory, antioxidant, and seboreregulating potential, and their lipophilic and volatile nature may facilitate interaction with the pilosebaceous environment, where acne lesions originate. Nevertheless, their therapeutic use requires careful formulation, because undiluted or poorly standardized essential oils can irritate the skin, disrupt the barrier, or trigger sensitization. Thus, the dermatological relevance of essential oils depends not only on their biological activity, but also on concentration, vehicle, stability, oxidation status, and patient tolerability [9,10].

Clinical evidence specifically evaluating *Melaleuca alternifolia* oil remains promising but limited, and systematic assessment of randomized controlled trials indicates that tea tree oil has been studied for several human health applications, including dermatological conditions, but the quality and heterogeneity of the trials limit the strength of the recommendations, and for acne, available evidence supports a potential benefit, particularly for mild to moderate cases, but further controlled studies using standardized formulations and validated acne severity scores are needed [11].

Recent reviews of essential oils in skin care and medicinal plants promoted for acne also support a cautious interpretation, and while natural products are frequently perceived by patients as safer or more acceptable, scientific evaluation must distinguish biologically plausible activity from clinically proven efficacy. In this regard, tea tree oil occupies a stronger position than many other plant-derived agents because it has mechanistic plausibility, dermatological use, and some clinical evaluation, and however, its role should remain complementary, formulation-dependent, and guided by safety considerations [12,13], and the framework of evidence supporting the discussion of tea tree oil and essential oils in acne vulgaris, including their biological reasoning, clinical interpretation, and safety considerations, is summarized by us to be easier to follow in Table 2.

Table 2. Evidence framework for tea tree oil and essential oils in acne vulgaris

Topic	Main relevance to acne vulgaris	Interpretation for the review	Ref.
Tea tree oil properties	Antibacterial, anti-inflammatory, and antioxidant activity	Central essential oil candidate for acne	[8]
Tea tree oil in acne	Potential reduction of inflammatory lesions, mainly papules and pustules	Promising but not definitive evidence	[8]
Essential oils in acne	Multiple oils show antimicrobial or anti-inflammatory potential	Provides broader phytotherapeutic context	[9]
Essential oils in inflammatory skin disease	Possible role in inflammatory dermatoses	Supports dermatological rationale, but requires safety caution	[10]
Randomized clinical evidence for tea tree oil	Evaluates efficacy and safety across human studies	Evidence exists, but study heterogeneity limits conclusions	[11]
Essential oils in skin care	Formulation, innovation, efficacy, and safety issues	Highlights the importance of the vehicle and tolerability	[12]
Medicinal plants for acne	Natural products are frequently promoted for acne	Need for evidence-based evaluation of phytotherapeutic claims	[13]

Mechanisms of action and formulation strategies

The therapeutic interest in tea tree oil for acne vulgaris is mainly supported by its antimicrobial, anti-inflammatory, and antibiofilm potential, and since *Cutibacterium acnes* is involved in acne pathogenesis through strain-dependent virulence, inflammatory activation, and biofilm formation, topical agents that reduce bacterial activity without promoting classical antibiotic resistance are clinically relevant, and comparative studies evaluating essential oils against *C. acnes* strains with different virulence patterns suggest that essential oils may exert variable antimicrobial effects depending on bacterial phylotype and oil composition, and this indicates that tea tree oil activity should not be interpreted as uniform but rather as dependent on chemical standardization, concentration, formulation, and the target strain's susceptibility [14].

Phytochemicals have also been investigated as complementary strategies against *C. acnes*, and their relevance lies in their ability to interfere with bacterial growth, inflammatory signaling, oxidative stress, and possibly biofilm-associated persistence, and in this context, tea tree oil can be integrated into a broader phytotherapeutic framework, where plant-derived bioactive compounds are explored as adjuvants for mild acne vulgaris and such agents may be especially useful when conventional treatments are limited by irritation, patient adherence, or concerns regarding long-term antibiotic use [15,16].

Formulation strategy is essential for translating tea tree oil from a biologically active essential oil into a dermatologically acceptable topical product, because essential oils are volatile and potentially irritant; appropriate delivery systems are needed to improve stability, control release, reduce direct irritation, and enhance contact with acne-associated microorganisms, and recent biomaterial-based approaches, such as bacterial cellulose modified with hydrolyzed collagen and loaded with tea tree oil, illustrate how formulation engineering

may improve antibacterial activity against acne-associated bacteria while providing a more controlled topical platform [17].

Biofilm formation is another relevant target in acne management, and *C. acnes* biofilms may contribute to bacterial persistence, inflammatory stimulation, and reduced therapeutic responsiveness, and therefore, active substances that affect biofilm organization or viability may provide additional benefits beyond simple planktonic bacterial inhibition and overall, tea tree oil-based strategies should be understood as formulation-dependent interventions whose potential value depends on antimicrobial activity, biofilm modulation, tolerability, and compatibility with evidence-based acne treatment [18], and we have made a concise synthesis of antimicrobial, antibiotic, phytochemical, and formulation-related aspects relevant to tea tree oil-based approaches in acne vulgaris is presented in Table 3.

Table 3. Mechanisms of action and formulation strategies relevant to tea tree oil in acne vulgaris

Component	Role in acne management	Practical relevance	Ref.
Antimicrobial activity	Inhibits acne-associated bacteria, including <i>Cutibacterium acnes</i>	Supports use as a non-antibiotic adjunct	[14]
Strain-dependent activity	Essential oil efficacy may vary according to <i>C. acnes</i> phylotype and virulence	Highlights the need for standardized testing	[14]
Phytochemical effects	May reduce bacterial growth, inflammation, and oxidative stress	Places tea tree oil within broader plant-derived acne therapies	[15,16]
Controlled topical formulation	Improves stability, release, and local tolerability	Reduces risks associated with direct essential oil exposure	[17]
Biomaterial-based delivery	Tea tree oil-loaded bacterial cellulose may enhance antibacterial performance	Supports the development of advanced topical platforms	[17]
Antibiofilm activity	Targets <i>C. acnes</i> biofilm persistence	Relevant for chronic or treatment-resistant acne	[18]

Dermatological safety, adverse reactions, and clinical limitations

Although tea tree oil has biologically plausible properties for acne vulgaris, its dermatological use requires careful safety evaluation, and essential oils are complex mixtures of volatile compounds, and their topical application may produce irritant reactions, allergic contact dermatitis, or, more rarely, systemic allergic manifestations, and this is particularly relevant for acne patients, whose skin barrier may already be altered by inflammation, excessive cleansing, topical retinoids, benzoyl peroxide, or previous antibiotic-based regimens, and therefore, the tolerability of tea tree oil depends not only on the oil itself, but also on concentration, vehicle, oxidation status, frequency of application, and individual susceptibility.

Reported cases of allergic contact dermatitis caused by tea tree oil highlight the need for caution when using over-the-counter products containing this ingredient, cutaneous reactions may include erythema, pruritus, edema, vesiculation, and spreading dermatitis beyond the initial application site, and such reactions are clinically important because patients often perceive natural products as inherently safe and may apply them repeatedly or in undiluted forms, and tea tree oil should not be recommended as a self-applied, undiluted topical agent, particularly in patients with sensitive skin, atopic tendency, a history of contact allergy, or active irritant dermatitis [19].

Systemic allergic contact dermatitis has also been reported after use of tea tree oil-containing topical preparations, suggesting that sensitization may extend beyond localized irritation, and although such reactions are uncommon, they reinforce the importance of standardized formulations, dermatological supervision, appropriate labeling, and patch testing when allergy is suspected, and from a clinical perspective, adverse reactions may be difficult to distinguish from acne flare, irritant dermatitis caused by conventional therapy, or worsening inflammation; therefore, careful history and temporal correlation with product use are essential [20].

The main limitation of tea tree oil in acne management is that current evidence does not support its use as a replacement for guideline-based therapy; its role is better interpreted as a potential adjunctive option in selected patients with mild to moderate acne, particularly when formulated at appropriate concentrations and combined with standard dermatological care, and future studies should define the optimal concentration, formulation stability, tolerability profile, treatment duration, and comparative efficacy relative to established topical agents, and until stronger clinical evidence is available, tea tree oil should be used cautiously, with emphasis on safety, patient education, and avoidance of undiluted application [19,20].

Conclusions

Tea tree oil is considered to be a plausible biological topical adjuvant in acne vulgaris, supported by antimicrobial, anti-inflammatory, antioxidant and antibiofilm mechanisms that align with key pathogenic processes involving *Cutibacterium acnes*, follicular inflammation and microbial dysbiosis but still, despite promising and limited preclinical evidence, the dermatological value of this oil remains highly dependent on the quality of the formulation, concentration, tolerability, and patient selection, while the risk of irritant or allergic contact dermatitis requires cautious use, avoidance of undiluted application, and positioning as a complementary strategy, not as a substitute for evidence-based therapy for acne.

References

1. Vasam M, Korutla S, Bohara RA: *Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances*. **Biochem Biophys Rep**. 2023. 36,101578. doi: 10.1016/j.bbrep.2023.101578.
2. Eichenfield DZ, Sprague J, Eichenfield LF: *Management of Acne Vulgaris: A Review*. **JAMA**. 2021. 326,20,2055-2067. doi: 10.1001/jama.2021.17633.
3. Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, Freeman EE, Keri JE, Stein Gold LF, Tan JKL, Tollefson MM, Weiss JS, Wu PA, Zaenglein AL, Han JM, Barbieri JS: *Guidelines of care for the management of acne vulgaris*. **J Am Acad Dermatol**. 2024. 90,5,1006.e1-1006.e30. doi: 10.1016/j.jaad.2023.12.017.
4. Kutlu Ö, Karadağ AS, Wollina U: *Adult acne versus adolescent acne: a narrative review with a focus on epidemiology to treatment*. **An Bras Dermatol**. 2023. 98,1,75-83. doi: 10.1016/j.abd.2022.01.006.
5. Mias C, Mengeaud V, Bessou-Touya S, Duplan H: *Recent advances in understanding inflammatory acne: Deciphering the relationship between Cutibacterium acnes and Th17 inflammatory pathway*. **J Eur Acad Dermatol Venereol**. 2023. 37 Suppl 2,3-11. doi: 10.1111/jdv.18794.
6. Dreno B, Dekio I, Baldwin H, Demessant AL, Dagnelie MA, Khammari A, Corvec S: *Acne microbiome: From phyla to phylotypes*. **J Eur Acad Dermatol Venereol**. 2024. 38,4,657-664. doi: 10.1111/jdv.19540.
7. Beig M, Shirazi O, Ebrahimi E, Banadkouki AZ, Golab N, Sholeh M: *Prevalence of antibiotic-resistant Cutibacterium acnes (formerly Propionibacterium acnes) isolates, a*

- systematic review and meta-analysis. **J Glob Antimicrob Resist**. 2024. 39,82-91. doi: 10.1016/j.jgar.2024.07.005.
8. Nascimento T, Gomes D, Simões R, da Graça Miguel M: *Tea Tree Oil: Properties and the Therapeutic Approach to Acne-A Review*. **Antioxidants (Basel)**. 2023. 12,6,1264. doi: 10.3390/antiox12061264.
 9. Nurzyńska-Wierdak R, Pietrasik D, Walasek-Janusz M: *Essential Oils in the Treatment of Various Types of Acne-A Review*. **Plants (Basel)**. 2022. 12,1,90. doi: 10.3390/plants12010090.
 10. Dontje AEWK, Schuiling-Veninga CCM, van Hunsel FPAM, Ekhardt C, Demirci F, Woerdenbag HJ: *The Therapeutic Potential of Essential Oils in Managing Inflammatory Skin Conditions: A Scoping Review*. **Pharmaceuticals (Basel)**. 2024. 17,5,571. doi: 10.3390/ph17050571.
 11. Kairey L, Agnew T, Bowles EJ, Barkla BJ, Wardle J, Lauche R: *Efficacy and safety of Melaleuca alternifolia (tea tree) oil for human health-A systematic review of randomized controlled trials*. **Front Pharmacol**. 2023. 14,1116077. doi: 10.3389/fphar.2023.1116077.
 12. Pezantes-Orellana C, German Bermúdez F, Montalvo J, Packer T, Orellana-Manzano A: *Evaluating efficacy, safety, and innovation in skin care applications of essential oils: a systematic review*. **Front Med (Lausanne)**. 2025. 12,1589691. doi: 10.3389/fmed.2025.1589691.
 13. Parvizi MM, Saki N, Rostami Ghotbabadi Z, Kamali M, Salmanpour N, Namazi M, Pasalar M: *Medicinal Plants for Acne Vulgaris: An Evidence-Based Review of Treatments Promoted by Social Media*. **J Cosmet Dermatol**. 2026. 25,1,e70628. doi: 10.1111/jocd.70628.
 14. Oliveira AS, Gaspar C, Rolo J, Palmeira-de-Oliveira R, Teixeira JP, Martinez-de-Oliveira J, Palmeira-de-Oliveira A: *Comparative efficacy of essential oils against Cutibacterium acnes: Effect upon strains from phylotypes with different virulence patterns*. **Microb Pathog**. 2025. 199,107159. doi: 10.1016/j.micpath.2024.107159.
 15. Sun C, Na Y, Wang Z, Zhu T, Liu X: *Phytochemicals, promising strategies combating Cutibacterium acnes*. **Front Pharmacol**. 2024. 15,1476670. doi: 10.3389/fphar.2024.1476670.
 16. Cristani M, Micale N: *Bioactive Compounds from Medicinal Plants as Potential Adjuvants in the Treatment of Mild Acne Vulgaris*. **Molecules**. 2024. 29,10,2394. doi: 10.3390/molecules29102394.
 17. Salawudeen T, Jomrit J, Kaewpradit S, Nokkaew N, Jantararat C: *Hydrolyzed collagen-modified bacterial cellulose loaded with tea tree oil for antibacterial activity against acne-associated bacteria*. **RSC Adv**. 2026. 16,10,9307-9320. doi: 10.1039/d5ra09816e.
 18. Ruffier d'Epenoux L, Fayoux E, Veziers J, Dagnelie MA, Khammari A, Dréno B, Corvec S: *Biofilm of Cutibacterium acnes: a target of different active substances*. **Int J Dermatol**. 2024. 63,11,1541-1550. doi: 10.1111/ijd.17194.
 19. Ambrogio F, Foti C, Cazzato G, Mortato E, Mazzocchi S, De Caro AP, Cassano N, Vena GA, Calogiuri G, Romita P: *Spreading Allergic Contact Dermatitis to Tea Tree Oil in an Over-the-Counter Product Applied on a Wart*. **Medicina (Kaunas)**. 2022. 58,5,561. doi: 10.3390/medicina58050561.
 20. Navarro-Triviño FJ, Prados-Carmona Á, Ruiz-Villaverde R: *Systemic allergic contact dermatitis caused by tea tree oil in a cream for treatment of molluscum contagiosum*. **Contact Dermatitis**. 2022. 87,3,285-287. doi: 10.1111/cod.14138.

Received: March 27, 2026

Accepted: June 05, 2026